ASRT PEER ANALYSIS

Assertio Therapeutics Inc — metric-by-metric comparison with peers and the industry median

ASRTAssertio Therapeutics Inc

🇺🇸 USA · NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic

Value it Duel

Overall Profile & Returns

· Drug Manufacturers - Specialty & Generic

Position Within Industry

0 = weak quartile, 100 = strong quartile

ASRTIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year

Split-adjusted

Year-to-Date (YTD)

Key Metric Comparison

P/E

Lower is better

ROE

Higher is better

Net Margin

Higher is better

Revenue Growth

Higher is better

All Metrics

Valuation
Metric	ASRT	DEVA	TLRY	HIK	HLN	GENIL	Ind. Median
P/E	—	—	—	12.27●	31.38	46.82	21.55
P/B	2.00	0.49	0.31●	1.91	1.98	3.47	1.91
EV/EBITDA	—	6.51●	—	9.24	19.20	14.07	12.18
P/S	1.48	0.68	0.56●	1.47	3.95	1.86	2.13

Financial Health
Metric	ASRT	DEVA	TLRY	HIK	HLN	GENIL	Ind. Median
Current Ratio	1.82	2.00	2.79●	1.82	0.92	1.33	2.22
Debt/Equity	53.3%	23.1%	20.4%●	61.8%	52.3%	41.0%	46.3%
NetDebt/EBITDA	5.39	0.89	-0.07●	1.87	3.50	1.10	1.24

Profitability
Metric	ASRT	DEVA	TLRY	HIK	HLN	GENIL	Ind. Median
Net Margin	-34.9%	-4.4%	-158.8%	12.0%	12.6%●	4.0%	4.0%
ROE	-38.8%	-3.6%	-63.6%	16.4%●	6.3%	8.7%	6.4%
ROA	-14.3%	-2.5%	-49.7%	7.5%●	3.2%	4.8%	3.4%
EBITDA Margin	-5.7%	12.0%	-156.2%	20.0%	25.2%●	14.3%	18.2%

Growth + Dividend
Metric	ASRT	DEVA	TLRY	HIK	HLN	GENIL	Ind. Median
Rev. Growth	-14.2%	7.7%	3.8%	7.4%	-26.7%	16.3%●	7.5%
NI Growth	—	—	—	12.2%	-14.2%	146.6%●	5.0%
Div. Yield	—	0.0%	—	5.4%●	2.0%	0.0%	2.0%
Payout	—	0.0%	—	45.2%	40.0%	0.0%	0.8%

Valuation
Metric	ASRT	ANIK	SIGA	ORGO	EOLS	EBS	Ind. Median
P/E	—	—	12.98	—	—	—	21.55
P/B	2.00	1.60	1.73	0.84	-15.72●	0.90	1.91
EV/EBITDA	—	—	4.29●	8.00	—	5.71	12.18
P/S	1.48	1.85	2.80	0.62●	1.50	0.69	2.13

Financial Health
Metric	ASRT	ANIK	SIGA	ORGO	EOLS	EBS	Ind. Median
Current Ratio	1.82	4.46●	3.25	3.53	2.04	4.29	2.22
Debt/Equity	53.3%	19.2%	0.4%	18.6%	-573.0%●	109.7%	46.3%
NetDebt/EBITDA	5.39	3.30	-5.27	-0.57	-8.20●	2.68	1.24

Profitability
Metric	ASRT	ANIK	SIGA	ORGO	EOLS	EBS	Ind. Median
Net Margin	-34.9%	-9.5%	21.6%●	-0.1%	-14.4%	-1.3%	4.0%
ROE	-38.8%	-7.8%	11.0%●	-0.1%	—	-1.6%	6.4%
ROA	-14.3%	-6.0%	8.7%●	-0.1%	-20.0%	-0.6%	3.4%
EBITDA Margin	-5.7%	-4.0%	29.3%●	7.3%	-4.6%	22.8%	18.2%

Growth + Dividend
Metric	ASRT	ANIK	SIGA	ORGO	EOLS	EBS	Ind. Median
Rev. Growth	-14.2%	23.2%●	-22.1%	11.9%	9.6%	-29.9%	7.5%
NI Growth	—	—	-58.2%	—	—	—	5.0%
Div. Yield	—	—	16.5%●	3.6%	—	—	2.0%
Payout	—	—	213.6%	-4,093.3%	—	—	0.8%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on ASRT

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jun 26, 26. This content is for informational purposes only and is not investment advice.